Biotech Values

[DewDiligence]

IDIX 2008-2009 Clinical Goals

[Updated based on guidance
from Susquehanna webcast.]


HIV

Mid 2008: Complete phase-1/2 IDX899 7-day monotherapy study using lower doses than 800mg. (Data from the 800mg cohort were reported on 2/6/08: #msg-26606685.) Report results at a medical conference in June.

3Q08: Start phase-2 IDX899 6-week combination study, IDX899+Truvada vs Sustiva+Truvada in first- and second-line patients.

End 2008: Partner IDX899 program following above phase-2 study.


HCV

April 2008: Report preclinical data on IDX184 at EASL (#msg-27106080).

Mid 2008: File IND/CTA for IDX184.

End 2008: Report initial human data for IDX184.

1H09: File IND/CTA for HCV protease inhibitor.